Table 6. Numbers of individuals with available biomarker measurements for the cases and controls included in the nested case-control studies of amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
| Biomarker analysed | Total number of individuals with at least one measurement | Number (%) of individuals by number of measurements | Total number of measurements | |||||
|---|---|---|---|---|---|---|---|---|
| 1 measurement | 2 measurements | 3 measurements | 4 measurements | 5 measurements | 6 or more measurements | |||
| Nested case-control study of ALS | ||||||||
| Leukocyte | ||||||||
| Cases | 226 | 123 (54.4%) | 45 (19.9%) | 17 (7.5%) | 9 (4.0%) | 7 (3.1%) | 25 (11.1%) | 546 |
| Controls | 5,621 | 3,209 (57.1%) | 1,093 (19.4%) | 525 (9.3%) | 270 (4.8%) | 147 (2.6%) | 377 (6.7%) | 12,255 |
| Haptoglobin | ||||||||
| Cases | 497 | 251 (50.5%) | 106 (21.3%) | 62 (12.5%) | 38 (7.6%) | 8 (1.6%) | 32 (6.4%) | 1,100 |
| Controls | 12,402 | 6,790 (54.7%) | 2,697 (21.7%) | 1,213 (9.8%) | 657 (5.3%) | 378 (3.0%) | 667 (5.4%) | 25,654 |
| Immunoglobulin-G | ||||||||
| Cases | 178 | 142 (79.8%) | 22 (12.4%) | 7 (3.9%) | 4 (2.2%) | 2 (1.1%) | 1 (0.6%) | 240 |
| Controls | 4,412 | 3,537 (80.2%) | 630 (14.3%) | 155 (3.5%) | 50 (1.1%) | 21 (0.5%) | 19 (0.4%) | 5,698 |
| Uric acid | ||||||||
| Cases | 559 | 257 (46.0%) | 113 (20.2%) | 75 (13.4%) | 45 (8.0%) | 18 (3.2%) | 51 (9.1%) | 1,445 |
| Controls | 13,953 | 6,997 (50.1%) | 3,001 (21.5%) | 1,521 (10.9%) | 820 (5.9%) | 522 (3.7%) | 1,092 (7.8%) | 32,813 |
| Nested case-control study of PD | ||||||||
| Leukocyte | ||||||||
| Cases | 1,682 | 887 (52.7%) | 337 (20.0%) | 159 (9.4%) | 75 (4.4%) | 67 (4.0%) | 157 (9.3%) | 4,150 |
| Controls | 41,639 | 23,037(55.3%) | 7,894 (19.0%) | 3,797 (9.1%) | 2,082 (5.0%) | 1,319 (3.2%) | 3,510 (8.4%) | 97,763 |
| Haptoglobin | ||||||||
| Cases | 3,375 | 1,712 (50.1%) | 747 (22.1%) | 359 (10.6%) | 222 (6.6%) | 121 (3.6%) | 214 (6.3%) | 7,440 |
| Controls | 83,967 | 44,151(52.6%) | 17,857 (21.3%) | 8,774 (10.4%) | 5,064 (6.0%) | 2,992 (3.6%) | 5,129 (6.1%) | 181,967 |
| Immunoglobulin-G | ||||||||
| Cases | 1,329 | 1,018 (76.6%) | 213 (16.0%) | 51 (3.8%) | 23 (1.7%) | 8 (0.6%) | 16 (1.2%) | 1,844 |
| Controls | 32,381 | 25,475(78.7%) | 4,932 (15.2%) | 1,258 (3.9%) | 398 (1.2%) | 133 (0.4%) | 185 (0.6%) | 42,756 |
| Uric acid | ||||||||
| Cases | 3,882 | 1,831 (47.2%) | 820 (21.2%) | 441 (11.4%) | 259 (6.7%) | 172 (4.4%) | 359 (9.2%) | 9,851 |
| Controls | 96,774 | 46,919(48.5%) | 20,467 (21.2%) | 10,459(10.8%) | 6,212 (6.4%) | 3,870 (4.0%) | 8,847 (9.1%) | 241,099 |